LABU Direxion Daily S&P Biotech Bull 3X Shares Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
20:23
Aug 25
Labubu Trader Long-term investor
Author says they have been holding LABU since last week to express.
Author says they have been holding LABU since last week to express the bond-short-squeeze/risk-on thesis tied to long-end rates.
LABU 1ST
03:00
Jul 06
Lee Kwon-hee CEO, Economist 815 Money Talk (815머니톡)
Innovation trumps rates, biotech rallies.
US biotech indices (NBI) hit new highs despite elevated interest rates, demonstrating that innovation momentum overrides rate fears. Korean biotech's weakness is not due to rates; breakthroughs drive biotech regardless of monetary policy. Trade via leveraged LABU or the NBI index.
LABU 1ST
HIGH

About LABU Analyst Coverage

Buzzberg tracks LABU (Direxion Daily S&P Biotech Bull 3X Shares) across 2 sources. 2 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (100%). 2 total trade ideas tracked. Past 7 days: 1 bullish. Latest voices: Labubu Trader, Lee Kwon-hee.